Skip Navigation

European Heart Journal 1994 15(7):940-946;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LENZ, T.
Right arrow Articles by GOTZEN, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LENZ, T.
Right arrow Articles by GOTZEN, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension

T. LENZ{dagger}, K.-L. SCHULTE{ddagger}, B. WAGNER, J. LILIENTHAL* and R. GOTZEN

Department of Medicine, Klinikum Steglitz-Free University Berlin, Germany
{dagger}Department of Nephrology, University Hospital 60596 Frankfurt a.M., Germany
{ddagger}Department of Angiology Charité, 10117 Berlin, Germany
*DATAMAP GmbH Lörracher Str. 16, 79115 Freiburg, Germany

Received 7 July 1993; revised 11 February 1994; .

Correspondence: Bernd Wagner, PhD, Parke Davis GmbH Berlin, European Clinical Development, 79090 Freiburg/Brsg., Germany.

Abstract

This 8-week, double-blind, multicentre study compared the efficacy and safety of the combination of quinapril and hydrochlorothiazide (HCTZ) with each drug as monotherapy. Outpatients with moderate to severe hypertension defined as supine diastolic blood pressure (DBF) ≥ 105 mmHg and ≤ 120 mmHg at the end of a 2 to 4-week placebo-baseline period were randomly assigned to one of the three treatments: once-daily 10 mg quinapril plus 12.5 mg HCTZ or monotherapy with these doses. After 4 weeks, the doses were to be doubled for the remaining 4 weeks. Three hundred and sixty-eight patients were randomized to double-blind medication; 346 completed the study. Seven patients withdrew due to lack of efficacy. Four patients withdrew due to side effects. In all three treatment groups, clinically significant reductions in DBP were achieved. Combination therapy was statistically more effective than each component taken as monotherapy. Adverse events were infrequent in all treatment groups. No patients experienced symptomatic hypotension or orthostatic hypotension.

Key Words: Essential hypertension • quinapril • hydrochlorothiazide • combination therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.